Coya Therapeutics' CEO Arun Swaminathan discusses the company's focus on harnessing T-regs to treat neurodegenerative diseases
He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.